Exelixis (NASDAQ: EXEL) reports a Q3 loss of $0.24, 8 cents better than the analyst estimate of ($0.32). Revenue for ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE